Advertisement

6th Obesity and NASH Drug Development Summit 2022


The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders. With mounting competition for the market in obesity and all eyes on the next wave of NASH candidates, the 6th Obesity and NASH Drug Development Summit, (previously the NASH Summit) is dedicated to reuniting industry leaders in metabolic syndrome to consolidate targets directly implicated in disease pathology and traverse the regulatory hurdles to commercialization. Join 150+ industry pioneers in Boston including pioneers Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Pfizer, Inventiva, Regeneron, FDA, AstraZeneca, and more to advance your pipeline towards approved treatment.

When
November 29 ‐ December 1, 2022
Location
200 Stuart Street, Boston Massachusetts 02116 United States
Venue
Revere Hotel Boston Common
Link

Map

loading...

GET DIRECTIONS

Advertisement

Hot topics


Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.